ProBeam

W. Tristram Arscott, Reid F. Thompson, Lingshu Yin, Brendan Burgdorf, Maura Kirk, Edgar Ben-Josef,
Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications,
Physics and Imaging in Radiation Oncology,
Volume 8,
2018,
Pages 17-22,
ISSN 2405-6316,
https://doi.org/10.1016/j.phro.2018.11.004.
(http://www.sciencedirect.com/science/article/pii/S2405631618300484)

Example case shown planned with this RapidPlan model

• The model is designed to be used for treatment plans of single lesions of the Liver.
• The model was developed for patients with primary liver cancer but could be used also for metastatic patients with similar geometric conditions
• The model supports a single target structure and was designed for a dose prescription of 5 fractions of 10 Gy per fraction
• The dose-volume constraints at the basis of the cohort of plans used for the model training were derived from the NRG-GI003 clinical trial (NCT03186898 at clinicaltrials.gov)
• The scientific reference for this model is:  Cozzi et al. Strahlenther Oncol. 2020. doi: 10.1007/s00066-020-01664-2

_{Any reference to a "plan study" are simply what the organizers call each case and may not be a "study" in the FDA sense as they may not have been published in a peer reviewed journal.
Varian does not provide medical advice and these are illustrative examples only.
Leading plans by expert planner. Your results may vary.}